This website is for UK Healthcare Professionals only

Contact us

Please complete the form below and a member of the BOTOX® (botulinum toxin type A) team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.

BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).1

The BOTOX® (botulinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page.

Please enter First name
Please enter Last name
Please enter Role
E-mail address is not valid
Please enter Last name
Please enter Hospital name
Please enter hospital postcode

Please select the items you are interested in:

Please select one field.

Please note that there may be certain circumstances where we contact you in relation to important AbbVie product or information which we are required to provide to you or your patients as a matter of law, or in order to comply with the obligations we owe to you or them. This type of communications does not constitute as promotional communication.

You can withdraw your consent at any time by using the unsubscribe option in the email or contacting [email protected]. For further information about AbbVie’s privacy practices, please refer to the AbbVie Privacy notice.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again.



1. BOTOX® Summary of Product Characteristics. Available at: Accessed March 2024

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.


Adverse events should be reported. Reporting forms and information can be found at or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

Adverse events should also be reported to AbbVie on [email protected]

Date of preparation: March 2024. UK-BCM-240034.